Clinical trial · Observational
Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies
Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies - ALARM3
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pediatric acute myeloid leukemias are disease with poor prognosis (overall survival of 60-75%) and high relapse rate of 35-45% require further understanding of the underlying biological mechanisms. The main objective of this study is to establish a biological collection to evaluate the genomic profiling of leukemic cells from primary blasts at diagnosis and/or relapse to improve identification of the main genetic hits involved in resistance and could predict a high risk of relapse. Other objectives include the study of bone marrow mesenchymal stem cells and ex vivo drug testing.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| Genetic Predisposition to Disease | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Collection of blood sample of bone marrow (cohort 1) | Other | — | UNRESOLVED |
| Collection of blood sample of bone marrow (cohort 2 and 3) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Cohort 1 : Patients with acute myeloid leukemia
- description
- Patients with acute myeloid leukemia at initial diagnosis or relapse, aged less than 25 years
- interventionNames
- Other: Collection of blood sample of bone marrow (cohort 1)
- label
- Cohort 2 : Patients with genetic predisposition to develop acute myeloid leukemia
- interventionNames
- Other: Collection of blood sample of bone marrow (cohort 2 and 3)
- label
- Cohort 3 : Patients who undergo bone marrow aspirate
- description
- Patients who undergo bone marrow aspirate as part of standard of care but without AML nor predisposition to develop AML, as controls
- interventionNames
- Other: Collection of blood sample of bone marrow (cohort 2 and 3)
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 25 Years
Show eligibility criteria text
Inclusion Criteria: * 0-25 years old * Newly diagnosed de novo or secondary Acute Myeloid Leukemia (AML) or * Relapsed or refractory AML or * Patients with genetic predisposition to develop AML or * Patients without haematological malignancy nor AML genetic predisposition syndrome who undergo bone marrow aspirate as part of standard of care * Signed informed consent of parents for patients aged less than 18 years old or signed informed consent of the patient for patients aged 18 and over. Exclusion Criteria: * Refuse to participate * Chronic myeloid leukemia (CML) * Lack of health insurance (French social security) * Under protection (tutelle, curatelle or sauvegarde de justice) * Pregnancy or breastfeeding
References
Publications (0)
Data not yet available